The study, conducted at the National Center for Global Health and Medicine in Tokyo and published in BMC Endocrine Disorders, was led by Erika Sugito and Noriko Ihana-Sugiyama together with colleagues including Akiyo Tanabe. The researchers set out to address a deceptively simple question that has long lacked a rigorous answer. Graves’ disease, the autoimmune disorder in which antibodies stimulate the thyroid into overproduction, is the most common cause of sustained thyrotoxicosis, and low neutrophil counts are occasionally observed in these patients at the time of diagnosis. But whether that association is specific to Graves’ disease, or simply a feature of the hyperthyroid state itself, has remained unclear because most prior work examined only single disease groups without an appropriate comparator.

The design was deliberately conservative. The team identified all adults newly diagnosed with thyrotoxicosis at their tertiary endocrinology center between August 1, 2016, and August 31, 2021. From an initial pool of 373 patients, they applied exclusion criteria designed to strip away confounders that could independently lower neutrophil counts: anyone with an underlying condition known to cause cytopenia, and anyone taking medications known to affect neutrophils, were removed from the analysis. This filtering left 188 patients for the final comparison, a number that reflects how difficult it is to assemble a clean cohort in this field, since many patients with thyroid disease carry comorbidities or drug exposures that muddy the hematologic picture.

The remaining patients were sorted into four etiological groups, and the classification rested on a key immunological marker. One hundred fourteen patients had Graves’ disease confirmed by a positive test for thyroid-stimulating hormone receptor antibodies, or TRAb, the autoantibodies that drive the disease. Twelve patients had TRAb-negative Graves’ disease, a less common presentation in which the clinical picture suggests Graves’ but the antibody test comes back negative. Thirty-seven patients had painless thyroiditis, a form of thyroid inflammation that releases preformed hormone into the circulation without overproduction, and twenty-five had subacute thyroiditis, a painful, often post-viral inflammation of the gland. This four-way split allowed the investigators to ask whether the autoimmune, antibody-driven form of thyrotoxicosis behaves differently from the destructive forms with respect to blood counts.

Neutropenia was defined in the study as a neutrophil count below 1,800 cells per microliter of blood, a conventional clinical threshold below which infection risk begins to rise. The results showed a clear signal in one direction and an absence of signal in another. Median neutrophil counts were significantly higher in the subacute thyroiditis group than in the other three groups, suggesting that the acute inflammatory response typical of that condition may transiently push neutrophil production upward. Yet when the researchers looked at the proportion of patients who actually crossed the neutropenia threshold, the differences between groups failed to reach statistical significance. Neutropenia was found in 7.0 percent of the TRAb-positive Graves’ group, 8.3 percent of the TRAb-negative Graves’ group, and 10.8 percent of the painless thyroiditis group, with the subacute thyroiditis group showing the lowest frequency.

Two further analyses sharpened the interpretation. First, the researchers compared neutrophil counts between the TRAb-positive and TRAb-negative Graves’ disease groups and found them comparable, which argues against the idea that the detectable autoimmune antibody itself is what drives the low counts. Second, they examined whether the severity of thyroid hormone excess predicted the degree of neutropenia by correlating free thyroxine, or FT4, levels with neutrophil counts within each group. The correlation was absent. In other words, within each disease category, a patient with very high thyroid hormone levels was no more likely to have depressed neutrophils than a patient with milder biochemical derangement, which weighs against a simple dose-dependent effect of thyroid hormone excess on the bone marrow.

The biological backdrop to these findings is worth unpacking. Neutrophils are produced in the bone marrow from hematopoietic stem cells and circulate for only hours to days, making their counts a sensitive barometer of marrow output and peripheral consumption. Several mechanisms have been proposed to explain why thyrotoxic patients might run low. Autoimmune destruction of neutrophils, analogous to the autoimmune process attacking the thyroid itself in Graves’ disease, is one candidate. Direct suppression of granulopoiesis by excess thyroid hormone is another. A third possibility, often raised in the literature, is that antithyroid drugs such as methimazole and propylthiouracil, which are mainstays of Graves’ treatment, cause neutropenia as an adverse effect. By restricting the analysis to newly diagnosed, treatment-naive patients and excluding those on count-altering medications, the Japanese team effectively removed the drug effect from the equation and asked about the disease itself.

The answer they obtained, that neutropenia is not preferentially tied to Graves’ disease, carries practical consequences. Antithyroid drugs carry a well-known risk of severe agranulocytosis, a potentially life-threatening drop in neutrophils, and clinicians traditionally hesitate to prescribe them to patients who already have borderline or low counts at baseline. If pre-existing neutropenia turns out to be equally common across the thyrotoxicosis spectrum, then the presence of a low count at diagnosis cannot by itself be taken as evidence for a particular etiology, nor as a reason to favor one diagnostic pathway over another. Instead, the finding suggests that mild neutropenia in a thyrotoxic patient should prompt a careful search for other causes, including hematologic disorders, before it is attributed to the thyroid condition.

The authors themselves are careful about how far the conclusions can be pushed, and their caution is well founded. The cohort of 188 patients, while respectable for a single-center study, was modest, and the number of actual neutropenia events was small, with only a handful of patients in each group crossing the threshold. The subgroup sizes were also markedly imbalanced, ranging from 114 patients with TRAb-positive Graves’ disease down to just 12 with TRAb-negative disease, a disparity that severely limits statistical power to detect real differences between the smaller groups. With so few events, a true difference in prevalence could easily have escaped detection, and the authors explicitly state that their findings should be interpreted with caution and require confirmation in larger prospective studies.

Even so, the study represents a meaningful step forward in a corner of endocrinology where clinical folklore has often outpaced evidence. By assembling a contemporaneous, multi-etiology cohort at a single tertiary center, applying rigorous exclusion criteria, and anchoring the analysis to a standardized neutropenia definition, Sugito, Ihana-Sugiyama, and their colleagues have produced a benchmark against which future multicenter and prospective studies can be measured. The picture that emerges is one of a hematologic finding that accompanies thyrotoxicosis across its various forms at a roughly similar rate, apparently independent of antibody status and independent of the degree of hormone elevation. For clinicians, the message is to treat neutropenia in a thyrotoxic patient as a finding deserving of its own evaluation rather than as a signature of any single thyroid disease. For researchers, the message is that the question of mechanism, whether autoimmune, hormonal, or something else entirely, remains open, and that answering it will require cohorts far larger than any single center can provide.

Subject of Research: Prevalence of neutropenia across different etiological types of thyrotoxicosis in a Japanese retrospective cohort

Article Title: Neutropenia associated with different types of thyrotoxicosis: a Japanese cohort study

Article References: Sugito, E., Ihana-Sugiyama, N., Hashimoto, M., Kodani, N., Bouchi, R., Ohsugi, M., Ueki, K., & Tanabe, A. (2026). Neutropenia associated with different types of thyrotoxicosis: a Japanese cohort study. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02583-6

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02583-6

Keywords: thyrotoxicosis, Graves' disease, neutropenia, TRAb, painless thyroiditis, subacute thyroiditis, thyroid, endocrinology, hematology, retrospective cohort study, free thyroxine, Japan

Methimazole is a first-line antithyroid medication that works by blocking the enzyme thyroid peroxidase, thereby curtailing the synthesis of thyroid hormone in patients with autoimmune thyrotoxicosis, most commonly Graves’ disease. The drug is generally well tolerated, but its most feared adverse effect is agranulocytosis, an idiosyncratic hematologic reaction in which the absolute neutrophil count plummets, typically to below 0.5 × 10⁹ per liter. The incidence is low—classically estimated at 0.2 to 0.5 percent of treated patients—but the consequences can be devastating, because neutrophils are the principal cellular effectors of innate immunity against bacteria and fungi. Without them, mucosal barriers in the mouth, throat, and gut become portals for overwhelming infection.

In this case, the patient had been taking methimazole for approximately one month when she presented with fever, pharyngitis, abdominal pain, and diarrhea. The timing is clinically significant: methimazole-induced agranulocytosis most often emerges within the first two to three months of therapy, which is precisely the window in which guidelines recommend vigilance for symptoms such as sore throat and fever. Laboratory evaluation confirmed the severity of her condition, revealing an absolute neutrophil count of just 0.01 × 10⁹ per liter—essentially a complete absence of circulating neutrophils—alongside markedly elevated inflammatory markers indicating a systemic inflammatory response already in progress.

What distinguished this case from the typical presentation of drug-induced agranulocytosis was what imaging revealed next. Computed tomography confirmed an ileocolic intussusception, with the terminal portion of the small intestine having invaginated into the colon. Intussusception is common in infants, where it is usually idiopathic, but in adults it is rare and almost always associated with a pathological lead point such as a polyp, tumor, or—critically in this patient’s situation—disordered motility and inflammatory change driven by severe sepsis. Even more alarming, surgical findings showed transmural necrosis of the involved bowel segment, meaning the intestinal wall had died through its full thickness, a condition that rapidly becomes fatal without resection.

The clinical team faced a genuine dilemma. Emergency surgery in a patient with profound neutropenia and septic shock carries extraordinary risks: the patient has minimal capacity to heal, to fight surgical-site infection, or to withstand the physiological insult of laparotomy. Profound neutropenia has traditionally been regarded as a relative contraindication to major emergency surgery. Yet the authors argue that when septic shock results from intestinal necrosis, the necrotic bowel itself is the source of the sepsis, and no amount of antibiotics will achieve cure without source control. The patient underwent an emergency ileocolic resection with a temporary ileostomy, removing the dead segment and diverting the fecal stream to protect the anastomosis.

Perioperative and postoperative management was aggressively multidisciplinary. The team administered broad-spectrum intravenous antibiotics to cover the gut flora flooding into tissues and bloodstream, and administered granulocyte colony-stimulating factor, or G-CSF, a recombinant growth factor that stimulates the bone marrow to produce and release neutrophils. G-CSF has become standard supportive care in antithyroid drug-induced agranulocytosis, shortening the duration of neutropenia, although its effect on mortality in septic neutropenic patients remains debated. The patient also required multi-organ support in the intensive care unit, reflecting the degree to which septic shock had compromised her cardiovascular and other organ systems.

The authors place their case in the context of a literature review of comparable reports, noting that gastrointestinal complications of agranulocytosis—ranging from necrotizing enterocolitis-like presentations to sepsis-driven bowel perforation—are exceedingly uncommon but well documented. The mechanism they propose for the intussusception is instructive: sepsis and severe inflammation can disrupt normal intestinal peristalsis, creating uncoordinated, spastic bowel contractions. In an adult bowel already weakened by inflammatory injury and mucosal breakdown, these dyskinetic segments can serve as the lead point for telescoping. This reframes intussusception not merely as a mechanical accident but as a potential downstream consequence of systemic immunoparalysis and septic physiology.

The broader lessons of the case concern monitoring and clinical decision-making. The authors emphasize the critical need for vigilant hematologic surveillance in patients starting methimazole, particularly during the first months of therapy. Current practice varies internationally: routine serial white cell counts are not universally recommended because agranulocytosis is unpredictable and idiosyncratic, unrelated to dose in most cases, but all guidelines agree that any patient on antithyroid medication who develops fever or sore throat must have an urgent differential blood count. The message for patients is equally important—symptoms that might suggest an ordinary upper respiratory infection can, in this context, signal a hematologic emergency.

Equally consequential is the paper’s stance on surgery in neutropenic sepsis. By demonstrating a successful outcome after emergency bowel resection in a patient whose neutrophil count was essentially zero, the authors argue that profound neutropenia should not be treated as an absolute contraindication to life-saving source control. The decision framework they describe is one of weighing the mortality of untreated necrotic bowel—approaching certainty—against the substantial but potentially survivable risks of surgery supported by antibiotics, G-CSF, and intensive care. Their conclusion that a multidisciplinary approach involving emergency physicians, endocrinologists, hematologists, surgeons, and intensivists is essential for successful outcomes reflects a growing consensus in the management of complex drug toxicities.

The case also carries a public health dimension. Hyperthyroidism affects a substantial fraction of the population, particularly women, and antithyroid drugs remain the standard initial therapy worldwide, especially in regions where radioactive iodine and surgery are deferred or unavailable. Agranulocytosis, while rare, is a reminder that even familiar, decades-old medications demand respect for their idiosyncratic risks. The Fujian team’s detailed documentation—supported by funding from the Joint Funds for the Innovation of Science and Technology of Fujian Province and approved by their institutional ethics committee with the patient’s written informed consent—adds a valuable data point to a sparse literature, and offers clinicians a template for recognizing and responding to one of the most dangerous intersections of endocrinology, hematology, and emergency surgery.

Subject of Research: Methimazole-induced agranulocytosis complicated by sepsis and ileocolic intussusception

Article Title: Methimazole-induced agranulocytosis complicated by sepsis and ileocolic intussusception: a case report and literature review

Article References: Zhu, X., Zhang, H., Lin, J., Pang, M., Zhang, X., Dong, Y., Huang, Y., & Li, Y. (2026). Methimazole-induced agranulocytosis complicated by sepsis and ileocolic intussusception: a case report and literature review. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02569-4

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02569-4

Keywords: methimazole, agranulocytosis, sepsis, intussusception, hyperthyroidism, adverse drug reaction, G-CSF, neutropenia, thyrotoxicosis, emergency surgery, BMC Endocrine Disorders, case report